PharmaCyte Biotech shares surge 20.48% after-hours as CEO and director buy shares, boosting cash to $20M from Femasys sale.

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) surged 20.48% in after-hours trading, driven by multiple positive developments. The stock’s jump followed a series of insider purchases, including $80,000 in shares acquired by CEO Joshua Silverman and 60,000 shares purchased by director Jonathan Schechter at prices ranging from $0.7776 to $0.8436. These transactions, combined with the company’s recent $6.7 million equity sale of Femasys Inc., are expected to boost cash and marketable securities to $20 million from $13.3 million as of July 31, 2025. The strategic divestiture and insider confidence signaled improved financial health and capital management, aligning with the stock’s upward trajectory. The after-hours rally reflects investor optimism over enhanced liquidity and management’s alignment with shareholder interests.